Barrett-Lee, Peter

A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome

Wooster, R., Mangion, J., Eeles, R., Smith, S., Dowsett, M., Averill, D., Barrett-Lee, P., Easton, D. F., Ponder, B. A. J., & Stratton, M. R. (1992) · Nature Genetics

Male Breast Health StudiesSexual Differentiation and Disorders

Cited by 250

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 230

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 177

Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer

Burcombe, R., Chan, S., Simcock, R., Samanta, K., Percival, F., & Barrett-Lee, P. (2013) · Advances in Breast Cancer Research

Health Systems, Economic Evaluations, Quality of LifeHER2/EGFR in Cancer Research

Cited by 59